BILL ANALYSIS                                                                                                                                                                                                    



                                                                  AB 631
                                                                  Page  1


          ASSEMBLY THIRD READING
          AB 631 (Leno)
          As Amended May 26, 2005
          Majority vote 

           HEALTH              12-0        APPROPRIATIONS      17-1        
           
           ----------------------------------------------------------------- 
          |Ayes:|Chan, Aghazarian, Berg,   |Ayes:|Chu, Sharon Runner, Bass, |
          |     |Dymally, De La Torre,     |     |Berg, Calderon, Emmerson, |
          |     |Jones, Montanez,          |     |Mullin, Karnette, Klehs,  |
          |     |Nakanishi, Negrete        |     |Leno, Nakanishi, Nation,  |
          |     |McLeod, Richman,          |     |Oropeza, Ridley-Thomas,   |
          |     |Ridley-Thomas, Strickland |     |Saldana, Walters, Yee     |
          |     |                          |     |                          |
          |-----+--------------------------+-----+--------------------------|
          |     |                          |Nays:|Haynes                    |
          |     |                          |     |                          |
           ----------------------------------------------------------------- 
           SUMMARY  :  Creates a licensing category for mobile narcotic  
          treatment programs.  Specifically,  this bill  :  

          1)Requires the California Department of Alcohol and Drug  
            Programs (ADP) to establish a program for the operation and  
            regulation of mobile narcotic treatment programs (MNTPs).

          2)Requires a MNTP to meet one of the following conditions:

             a)   Hold a primary narcotic treatment program license; or,

             b)   Be affiliated and associated with a primary licensed  
               narcotic treatment program.  A MNTP meeting this  
               requirement from being required to have a license separate  
               from the primary licensed narcotic treatment program with  
               which it is affiliated.

          3)Defines a MNTP as a program in which interested and  
            knowledgeable physicians, surgeons, counselors and authorized  
            licensed professionals provide addiction treatment services  
            and through which medication may be obtained directly through  
            the manufacturer or through the affiliated licensed narcotic  
            treatment program for distribution to patients and through  
            direct administration and specified dispensing services.









                                                                  AB 631
                                                                  Page  2


          4)Defines authorized staff as program directors, medical  
            directors, program physicians, physician extenders, counselors  
            and other staff, as defined in existing law.

          5)States that regardless of any other provision of law or  
            regulation, a MNTP that is affiliated or associated with a  
            licensed narcotic treatment program may be approved by the  
            department if all of the following conditions are met:

             a)   Each mobile office patient is registered as a patient in  
               the licensed narcotic treatment program and both the  
               licensed narcotic treatment program and the MNTP ensure  
               that all services, as required, for the management of  
               narcotic addiction are provided to all parties treated in  
               the remote site;

             b)   The primary licensed narcotic treatment program is  
               limited to its total licensed capacity as established by  
               ADP, including the patients of physicians in the mobile  
               narcotic treatment program;

             c)   Pharmacologic treatment that has been approved by the  
               federal Food and Drug Administration is administered; and,

             d)   Protocols are developed to prevent the diversion of  
               medication.

          6)Requires ADP, in considering a MNTP application, to  
            independently weigh the treatment needs and concerns of the  
            county, city, or areas to be served by the program.

          7)Specifies that nothing in this bill is intended to expand the  
            scope of the practice of pharmacy.

          8)Requires the MNTPs to be located at predetermined sites  
            approved by ADP.  

           EXISTING LAW : 

          1)Establishes ADP to develop and implement a statewide plan to  
            alleviate problems related to inappropriate alcohol use, and  
            licenses alcoholism and drug abuse recovery or treatment  
            facilities that provide a broad range of services in a  
            supportive environment for adults who are addicted to alcohol  








                                                                  AB 631
                                                                  Page  3


            or drugs.

          2)Specifies that ADP is the single agency authorized to receive  
            federal funds for substance abuse and to expend those funds,  
            as specified.

          3)Requires ADP to apply for federal block grant funds from the  
            federal Substance Abuse and Mental Health Services  
            Administration (SAMHSA) and may expend those funds only upon  
            appropriation of and approval by the Legislature.

           FISCAL EFFECT  :  According to the Assembly Appropriations  
          Committee:

          1)Unknown General Fund cost pressures in the Drug Medi-Cal  
            program to the extent this bill increases the number of  
            counties that start MNTPs and the number of clients served by  
            newly licensed programs.  For example, an increase in 35  
            patients, served at a rate of $13 per day would result in more  
            than $160,000 in Drug Medi-Cal costs, which are shared evenly  
            by the federal and state governments. 

          2)Unknown and potentially significant off-setting savings to the  
            extent that this bill reduces societal costs in terms of  
            incarceration, health care, and public benefits.  Some studies  
            indicate that savings accrue at a rate of $7 in the future to  
            every $1 spent on addiction treatment in the present. 

           COMMENTS  :  According to the author, this bill will make services  
          offered by MNTPs eligible for Medi-Cal and will expand access to  
          effective treatment services.  In illustrating the need for this  
          bill, the author cites the mobile narcotic treatment pilot  
          project in San Francisco which provides narcotic treatment  
          services to various individuals.  Although 21% of the patients  
          receiving services from the pilot project are eligible for  
          Medi-Cal, the services are currently not reimbursed because the  
          program is not licensed by ADP.

          In addition, the author states that locating traditional  
          methadone clinics is made difficult by community resistance to  
          the presence of treatment programs in their neighborhoods.   
          Mobile narcotic treatment programs would address this issue by  
          providing services in neighborhoods where the services are  
          needed without creating a permanent clinic site.








                                                                  AB 631
                                                                  Page  4



          In May 2002, the San Francisco Board of Supervisors passed a  
          resolution allowing the San Francisco Department of Public  
          Health to establish a mobile medication unit pilot program as an  
          extension to the city's narcotic treatment program.  To support  
          the pilot program, federal funding was granted by SAMHSA.  On  
          September 10, 2002, ADP allowed San Francisco to operate a  
          mobile medication unit pilot program to provide replacement  
          narcotic therapy from a van.  This van provides services daily  
          at two locations for up to 75 patients in each location.  The  
          van provides dispensing services, urinalysis sample collection  
          and emergency crisis counseling.  Scheduled counseling sessions  
          are provided in an office space at the community clinics where  
          the van is securely parked.  

          In California, individuals who are addicted to heroin or other  
          opiates may be admitted to a state approved NTP for replacement  
          narcotic therapy (RNT) using FDA approved medications.  NTP's  
          use Methadone and Levo-alpha-acetylmethadol for RNT.  To receive  
          these medications in a licensed NTP, all patients must  
          participate in a comprehensive treatment program which includes  
          a medical evaluation and screening for diseases that are  
          disproportionately represented in the opiate-addicted  
          populations.  Patients are evaluated and provided counseling for  
          medical, alcohol, criminal, and psychological problems and are  
          required to undergo regular urinalysis to ensure that illicit  
          drugs are not being used during treatment.  According to ADP,  
          methadone maintenance treatment costs an average $11 to $13 per  
          day.

          The NTP licensing branch at ADP is responsible for licensing  
          NTPs and regulating the delivery of replacement narcotic therapy  
          services to patients.  ADP ensures that patients enrolled in NTP  
          programs receive therapeutic care and ensure the health and  
          safety of each patient is upheld.  Annual inspections monitor  
          NTPs for compliance with state and federal laws and regulations.  
           In addition, programs are required to be certified by SAMHSA  
          and to obtain a Drug Enforcement Administration (DEA)  
          registration prior to licensure.  For purposes of the San  
          Francisco mobile medication unit pilot program, DEA required the  
          NTP to equip the van with a Global Positioning System and a  
          security system that provides security for the safe that stores  
          the medication, panic buttons throughout the van and a  
          monitoring device which allows a security company to monitor the  








                                                                  AB 631
                                                                  Page  5


          interior of the van in an emergency.  

          ADP receives Medi-Cal funding from the Department of Health  
          Services for eligible services provided to Medi-Cal  
          beneficiaries through an Interagency Agreement.  DMC benefits  
          are optional Medi-Cal benefits.  DMC services provide medically  
          necessary alcohol and other drug treatment to eligible Medi-Cal  
          recipients.  The services include Outpatient Drug Free  
          Treatment, Narcotic Treatment Program and Naltrexone Treatment.   
          In addition, Day Care Rehabilitative Treatment and Residential  
          Treatment are available to full scope Medi-Cal beneficiaries  
          under the age of 21 and to pregnant and postpartum women.

           
          Analysis Prepared by  :    Rosielyn Pulmano / HEALTH / (916)  
          319-2097 


                                                                FN: 0010858